Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
ShockWave Medical price target raised to $60 from $53 at Canaccord » 07:37
08/12/20
08/12
07:37
08/12/20
07:37
SWAV

ShockWave Medical

/

+

Canaccord analyst Jason…

Canaccord analyst Jason Mills raised the firm's price target on ShockWave Medical to $60 from $53 and keeps a Buy rating on the shares. The analyst noted is Q2 results exceeded expectations and that procedures bottomed in April and improved steadily thereafter with June and July sales improving. He said the company is putting the pieces together to accelerate momentum post-Covid.

ShowHide Related Items >><<
SWAV ShockWave Medical
/

+

SWAV ShockWave Medical
/

+

07/21/20 Piper Sandler
ShockWave '673 patent found to be invalid, says Piper Sandler
07/09/20 Canaccord
ShockWave Medical patent outcome impact minimal, says Canaccord
07/09/20 Piper Sandler
Piper sees 'key win' for ShockWave in claim 5 being upheld
07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
SWAV ShockWave Medical
/

+

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
/

+

Tuesday
Earnings
ShockWave Medical reports Q2 EPS (56c), consensus (62c) » 16:21
08/11/20
08/11
16:21
08/11/20
16:21
SWAV

ShockWave Medical

$52.34 /

+0.78 (+1.51%)

Reports Q3 revenue…

Reports Q3 revenue $10.29M, consensus $8.35M."The progress we made during this past quarter, despite the hurdles and challenges of COVID-19, reflects the commitment and strength of our team and the uniqueness of our proprietary IVL technology," said Doug Godshall, President and CEO of Shockwave Medical. "The continued interest and demand for IVL has really demonstrated how highly valued Shockwave's technology continues to be as a safe, effective, efficient option for our customers who treat severely calcified cardiovascular disease. All of us at Shockwave have a great deal of gratitude and respect for our partners on the provider side of the system for their dedication to patients, particularly under such challenging conditions. We are honored to have been given an opportunity to work with so many extraordinary healthcare professionals."

ShowHide Related Items >><<
SWAV ShockWave Medical
$52.34 /

+0.78 (+1.51%)

SWAV ShockWave Medical
$52.34 /

+0.78 (+1.51%)

07/21/20 Piper Sandler
ShockWave '673 patent found to be invalid, says Piper Sandler
07/09/20 Canaccord
ShockWave Medical patent outcome impact minimal, says Canaccord
07/09/20 Piper Sandler
Piper sees 'key win' for ShockWave in claim 5 being upheld
07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
SWAV ShockWave Medical
$52.34 /

+0.78 (+1.51%)

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$52.34 /

+0.78 (+1.51%)

Over a week ago
Recommendations
ShockWave '673 patent found to be invalid, says Piper Sandler » 05:11
07/21/20
07/21
05:11
07/21/20
05:11
SWAV

ShockWave Medical

$44.84 /

+0.48 (+1.08%)

, CSII

Cardiovascular Systems

$29.73 /

-0.87 (-2.84%)

The U.S. Patent Trial and…

The U.S. Patent Trial and Appeal Board yesterday found all challenged claims of ShockWave Medical's (SWAV) '673 patent are invalid, Piper Sandler analyst Adam Maeder tells investors in a research note. With the ruling, we now have initial decisions on all three inter partes review challenges regarding ShockWave's '673, '091, and '371 patents, the analyst points out. Although the scoreboard "heavily favors" Cardiovascular Systems (CSII), ShockWave still has a chance to appeal the invalidated claims, adds Maeder. The analyst says that more importantly, ShockWave has additional patents that could block a competitor from commercializing an intravascular lithotripsy device. Additionally, claim five from ShockWave's '371 patent was upheld earlier this month, which is an "important win," contends Maeder. The analyst says the company remains confident it will maintain exclusivity of IVL therapy. He maintains an Overweight rating on the shares with a $54 price target.

ShowHide Related Items >><<
SWAV ShockWave Medical
$44.84 /

+0.48 (+1.08%)

CSII Cardiovascular Systems
$29.73 /

-0.87 (-2.84%)

SWAV ShockWave Medical
$44.84 /

+0.48 (+1.08%)

07/09/20 Canaccord
ShockWave Medical patent outcome impact minimal, says Canaccord
07/09/20 Piper Sandler
Piper sees 'key win' for ShockWave in claim 5 being upheld
07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
06/11/20
Fly Intel: Top five analyst upgrades
CSII Cardiovascular Systems
$29.73 /

-0.87 (-2.84%)

07/17/20 Barclays
Cardiovascular Systems initiated with an Overweight at Barclays
06/19/20 Aegis
Cardiovascular Systems initiated with a Buy at Aegis
06/11/20 Needham
Needham upgrades Cardiovascular Systems on 'too compelling' valuation
SWAV ShockWave Medical
$44.84 /

+0.48 (+1.08%)

CSII Cardiovascular Systems
$29.73 /

-0.87 (-2.84%)

  • 17
    Jun
  • 10
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$44.84 /

+0.48 (+1.08%)

CSII Cardiovascular Systems
$29.73 /

-0.87 (-2.84%)

Hot Stocks
ShockWave Medical appoints Maria Sainz to board of directors » 08:15
07/20/20
07/20
08:15
07/20/20
08:15
SWAV

ShockWave Medical

$44.36 /

+0.65 (+1.49%)

Shockwave Medical…

Shockwave Medical announced that Maria Sainz has joined its Board of Directors and will serve on Shockwave's Compensation Committee. Ms. Sainz currently serves as CEO of Aegea Medical.

ShowHide Related Items >><<
SWAV ShockWave Medical
$44.36 /

+0.65 (+1.49%)

SWAV ShockWave Medical
$44.36 /

+0.65 (+1.49%)

07/09/20 Canaccord
ShockWave Medical patent outcome impact minimal, says Canaccord
07/09/20 Piper Sandler
Piper sees 'key win' for ShockWave in claim 5 being upheld
07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
06/11/20
Fly Intel: Top five analyst upgrades
SWAV ShockWave Medical
$44.36 /

+0.65 (+1.49%)

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$44.36 /

+0.65 (+1.49%)

Over a month ago
Recommendations
ShockWave Medical patent outcome impact minimal, says Canaccord » 07:40
07/09/20
07/09
07:40
07/09/20
07:40
SWAV

ShockWave Medical

$47.14 /

-0.53 (-1.11%)

Canaccord analyst Jason…

Canaccord analyst Jason Mills said the ShockWave Medical patent IPR was not optimal but he he expects to see little or no impact from the decision. He sees the implications as benign for both the company and its future positioning as he sees the company's expanding patent portfolio as expanding its strong competitive moat. Mills reiterated his Buy rating and $53 price target on ShockWave Medical shares.

ShowHide Related Items >><<
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

07/09/20 Piper Sandler
Piper sees 'key win' for ShockWave in claim 5 being upheld
07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

Recommendations
Piper sees 'key win' for ShockWave in claim 5 being upheld » 05:06
07/09/20
07/09
05:06
07/09/20
05:06
SWAV

ShockWave Medical

$47.14 /

-0.53 (-1.11%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder keeps an Overweight rating on ShockWave Medical with a $54 price target after the U.S. Patent Trial and Appeal Board found the company's '091 patent as invalid, and claims 1-4, 6-17 of the '371 patent as unpatentable. The '091 patent is "relatively narrow" and covers pulse sensing/termination, whereas the '371 patent is broader and covers the concept of an angioplasty catheter able to break calcium using shockwaves, Maeder tells investors in a research note. While the company disagrees with the invalidity rulings and will appeal, a "key win" is that claim 5 from the '371 patent was upheld, says the analyst. Maeder notes that this claim describes a device delivered over a guidewire that generates shockwaves using electrodes inside of a balloon catheter. ShockWave believes its broader patent estate provides additional protection from competition, he adds.

ShowHide Related Items >><<
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

07/08/20 Oppenheimer
ShockWave Medical ruling a negative, says Oppenheimer
06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform from Underperform at Oppenheimer
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$47.14 /

-0.53 (-1.11%)

Recommendations
ShockWave Medical ruling a negative, says Oppenheimer » 15:46
07/08/20
07/08
15:46
07/08/20
15:46
SWAV

ShockWave Medical

$47.11 /

-0.56 (-1.17%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia maintained a Perform rating on ShockWave Medical after the U.S. Patent Trial and Appeal Board ruled midday against ShockWave Medical. The analyst believes this decision is a negative, and "dents ShockWave's core IP claims, and eliminates a 'strategic appeal' to the story."

ShowHide Related Items >><<
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform from Underperform at Oppenheimer
06/09/20 Canaccord
ShockWave Medical price target raised to $53 from $46 at Canaccord
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

  • 17
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

Hot Stocks
U.S. PTAB rules ShockWave's claims of '091 patent 'unpatentable' » 15:46
07/08/20
07/08
15:46
07/08/20
15:46
SWAV

ShockWave Medical

$47.11 /

-0.56 (-1.17%)

, CSII

Cardiovascular Systems

$30.38 /

+0.05 (+0.16%)

The U.S. Patent Trial and…

The U.S. Patent Trial and Appeal Board, or PTAB, ruled against ShockWave Medical (SWAV) in IPR2019-00409: Cardiovascular Systems (CSII) v. Shockwave Medical - U.S. Patent No. 8728091, Shockwave Catheter System With Energy Control. The ruling stated that "Cardiovascular Systems has shown, by a preponderance of the evidence, that claims 1-14 of patent 8,728,091 are unpatentable."

ShowHide Related Items >><<
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

CSII Cardiovascular Systems
$30.38 /

+0.05 (+0.16%)

SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform from Underperform at Oppenheimer
06/09/20 Canaccord
ShockWave Medical price target raised to $53 from $46 at Canaccord
CSII Cardiovascular Systems
$30.38 /

+0.05 (+0.16%)

06/19/20 Aegis
Cardiovascular Systems initiated with a Buy at Aegis
06/11/20 Needham
Needham upgrades Cardiovascular Systems on 'too compelling' valuation
06/11/20 Needham
Cardiovascular Systems upgraded to Buy from Hold at Needham
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

CSII Cardiovascular Systems
$30.38 /

+0.05 (+0.16%)

  • 17
    Jun
  • 10
    Jun
  • 15
    Nov
SWAV ShockWave Medical
$47.11 /

-0.56 (-1.17%)

CSII Cardiovascular Systems
$30.38 /

+0.05 (+0.16%)

Syndicate
ShockWave Medical 1.7M share Secondary priced at $45.75 » 20:22
06/16/20
06/16
20:22
06/16/20
20:22
SWAV

ShockWave Medical

$46.13 /

+0.55 (+1.21%)

The offering priced below…

The offering priced below the last closing price of $46.10. Morgan Stanley and BofA are acting as joint book running managers for the offering.

ShowHide Related Items >><<
SWAV ShockWave Medical
$46.13 /

+0.55 (+1.21%)

SWAV ShockWave Medical
$46.13 /

+0.55 (+1.21%)

06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform from Underperform at Oppenheimer
06/09/20 Canaccord
ShockWave Medical price target raised to $53 from $46 at Canaccord
SWAV ShockWave Medical
$46.13 /

+0.55 (+1.21%)

  • 17
    Jun
SWAV ShockWave Medical
$46.13 /

+0.55 (+1.21%)

Syndicate
ShockWave Medical files to sell 1.7M shares of common stock » 07:42
06/16/20
06/16
07:42
06/16/20
07:42
SWAV

ShockWave Medical

$45.58 /

+0.95 (+2.13%)

Morgan Stanley and BofA…

Morgan Stanley and BofA Securities are acting as joint lead book-running managers for the offering.

ShowHide Related Items >><<
SWAV ShockWave Medical
$45.58 /

+0.95 (+2.13%)

SWAV ShockWave Medical
$45.58 /

+0.95 (+2.13%)

06/11/20
Fly Intel: Top five analyst upgrades
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform at Oppenheimer
06/11/20 Oppenheimer
ShockWave Medical upgraded to Perform from Underperform at Oppenheimer
06/09/20 Canaccord
ShockWave Medical price target raised to $53 from $46 at Canaccord
SWAV ShockWave Medical
$45.58 /

+0.95 (+2.13%)

SWAV ShockWave Medical
$45.58 /

+0.95 (+2.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.